Letter to the Editor
- Response to: Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”, Mariana P. Miranda-Hernández, Carlos A. López-Morales, Francisco C. Perdomo-Abúndez, Rodolfo D. Salazar-Flores, Nancy D. Ramírez-Ibanez, Nestor O. Pérez, Aaron Molina-Pérez, Jorge Revilla-Beltri, Emilio Medina-Rivero, and Luis F. Flores-Ortiz
Journal of Immunology Research
Letter to the Editor (3 pages), Article ID 6156024, Volume 2018 (2018)
Published 21 February 2018
Clinical Study
- New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept, Mariana P. Miranda-Hernández, Carlos A. López-Morales, Francisco C. Perdomo-Abúndez, Rodolfo D. Salazar-Flores, Nancy D. Ramírez-Ibanez, Nestor O. Pérez, Aarón Molina-Pérez, Jorge Revilla-Beltri, Luis F. Flores-Ortiz, and Emilio Medina-Rivero
Journal of Immunology Research
Clinical Study (9 pages), Article ID 9697080, Volume 2016 (2016)
Published 12 June 2016
Journal of Immunology Research
Volume 2018, Article ID 5047067, 3 pages
https://doi.org/10.1155/2018/5047067
Letter to the Editor
Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
1Pfizer Biotech, Dublin, Ireland
2Pfizer Biotech, Andover, MA, USA
Correspondence should be addressed to Brian Hassett; moc.rezifp@ttessah.nairb
Received 13 October 2016; Accepted 12 October 2017; Published 30 January 2018
Academic Editor: Ethan M. Shevach
Copyright © 2018 Brian Hassett et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
This article has no abstract.